Biomedical subjects

T J Potter

Publications and source records attributed to T J Potter.

9 recordsLinked to original sources

PubMed1994

Ontogeny of biphasic locomotor effects of quinpirole.

The effects of the dopamine D2/D3 receptor agonist quinpirole (LY171555) on locomotor activity were tested on rats of 10, 15, 20, 30, and 60 days of age. In two separate experiments, doses of 0 (vehicle), 0.02, 0.2, or 2.0 mg/kg quinpirole were injected SC into rats at each age, and their effects measured either for 2 h at 15-min intervals, or 30 min at 5-min intervals. At 10, 15, and 20 days of age, quinpirole significantly increased distance travelled in a dose-dependent manner. At 30 and 60 days of age, quinpirole significantly decreased distance travelled early in the session and increased it later. These results suggest that a dopamine autoreceptor begins to function between 20 and 30 days of age. Concomitant with the appearance of quinpirole-induced locomotor suppression early in the session, the amount of quinpirole-induced activation late in the session declined.

Aging↗

PubMed1993

Locomotor activity following intra-accumbens microinjections of dopamine D1 agonist SK&F 38393 in rats.

The present study examined the effects of the dopamine D1 receptor subtypes agonist SK&F 38393 on locomotor activities after bilateral microinjection (0.00, 0.01, 0.1, 1.0, 10.0 micrograms) into the nucleus accumbens (Acb). The dose of 0.1 microgram elicited the highest response rate across measures of locomotion, rearing and stereotypy behavior. On the other hand, the largest dose of 10.0 micrograms was associated with significant increase in center time behaviors. The data were supportive of the hypothesis that dose-related locomotor activities elicited by microinjections of SK&F 38393 into the Acb are independently mediated by D1 receptors.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗

PubMed1993

Biphasic effects of dopamine agonist N-0434 on locomotor behaviors in rats.

The effects of a dopamine agonist, (+/-)-2-(N-penylethyl-N-propyl)amino-5- hydroxytetralin (N-0434) (SC doses of 0.00, 0.01, 0.1, and 1.0 mg/kg) were tested in rats for 120 min in an activity monitor. The durations in seconds of horizontal locomotor time, rearing time, stereotypy time, and margin time (thigmotaxis) were measured during 12 10-min time blocks. N-0434 (0.1 and 1.0 mg/kg) resulted in biphasic effects (initial inhibition followed by potentiation) of linear locomotor time and an attenuation of thigmotaxis. The 0.1- and 1.0-mg/kg doses initially suppressed rearing time but had mixed potentiation effects. The 0.01- to 1.0-mg/kg doses suppressed stereotypy time. The differential behavioral profiles were discussed in reference to the functions of dopamine receptors.

Animals↗

PubMed1993

Effects of dopamine D1 antagonists SCH23390 and SK&F83566 on locomotor activities in rats.

The effects of the dopamine D1 antagonists R-(+)-7-chloro-8-hydroxy-3-methyl-1phenyl-2,3,4,5-tetrahydro-1-H-3 -benzazapine (SCH23390) and (+-)-7-bromo-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1- H-3-benzazapine (SK&F83566) were tested for 2 h on linear locomotor, rearing, stereotypy, and margin times in an open field. Each of the antagonists attenuated the duration of linear locomotion, rearing, and stereotypy times in a dose- and time-dependent manner. The effectiveness of the antagonists was relatively brief and SCH23390 was more effective than SK&F83566 on each behavior. The two antagonists had differential effects on margin time.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗

PubMed1992

Differential effects of dopamine D2 agonist quinpirole upon the dorsal immobility response in rats.

The effects of various dose levels of systemically injected quinpirole upon the dorsal immobility response (DIR) over a time course was investigated in male rats. A low dose of quinpirole (0.01 mg/kg) significantly attenuated the duration of the DIR following the 10-min interval, whereas the highest dose (1.0 mg/kg) had a biphasic effect so that at the 10-min interval the duration of the DIR was significantly potentiated and at the 60-min interval the duration of the DIR was significantly attenuated. The intermediate dose (0.1 mg/kg) had intermediate behavioral effects. The data support the growing evidence that quinpirole has differential effects upon behavior over time as a function of the dose levels. The present data were discussed in reference to presynaptic and postsynaptic dopamine D2 receptor theory.

Animals↗

PubMed1990

Effects of cholinergic agonists on the dorsal immobility response.

The effects of pilocarpine, arecoline, and physostigmine on the dorsal immobility response in ovariectomized female rats were tested. The effect of pretreatment with the cholinergic antagonist scopolamine was also tested. Pilocarpine, arecoline, and physostigmine all significantly decreased the duration of the dorsal immobility response in a dose-dependent way. Scopolamine significantly blocked the effect of pilocarpine. Thus, cholinergic agonists attenuate the dorsal immobility response via their effect on cholinergic systems in the central nervous system.

Animals↗

PubMed1988

Effect of bombesin and gastrin-releasing peptide on canine sphincter of Oddi.

This study reports the effects of bombesin and gastrin-releasing peptide (GRP) on the canine sphincter of Oddi using a method that allows repeated cannulation of the biliary sphincter in the unanesthetized animal through a Thomas cannula placed opposite the biliary papilla. Immediately after intravenous administration of bombesin or GRP, phasic sphincter contractions disappeared, basal sphincter pressures fell, and common bile duct pressures rose. Because bombesin releases cholecystokinin (CCK) and CCK resulted in a similar pattern to that of bombesin, the bombesin effect on the sphincter of Oddi may have been secondary to CCK's effect on the sphincter. To test if the bombesin effect on the sphincter of Oddi was due to the release of CCK, we blocked CCK release by administration of somatostatin, having first established that somatostatin blocked endogenous CCK release in our animal model by use of an intraduodenal infusion of lipid. Exogenous administration of bombesin failed to alter sphincter of Oddi or common bile duct pressures in dogs treated with somatostatin. Somatostatin did not, however, block CCK's effect on gallbladder contraction, since exogenous administration of CCK after somatostatin injection resulted in the pressure changes in the biliary tree typical of CCK-induced gallbladder contraction. Thus bombesin administration appears to result in sphincter relaxation and gallbladder contraction by the release of endogenous CCK rather than by a direct effect. The increase in common bile duct pressures was due to gallbladder contraction, since this rise in pressure was abolished by cholecystectomy. The peptide effect on sphincter contraction and basal sphincter pressure were unaffected by cholecystectomy.

Ampulla of Vater↗

PubMed1986

Pills in the colon.

Explore the source record for details and available documents.

Administration, Oral↗

PubMed1984

The effect of lactulose on psychomotor performance tests in alcoholic cirrhotics without overt hepatic encephalopathy.

Thirty-two alcoholic cirrhotics without clinical evidence of encephalopathy were randomized to lactulose or sucrose treatment in order to evaluate the effects of chronic lactulose therapy on five psychomotor performance tests. Statistically significant improvement was seen in three of the five tests in the lactulose-treated group, while no significant improvement in any test was noted in the sucrose group. However, because of the limited extent of improvement in the lactulose treated group, problems with medication intolerance, and lack of improvement in complex psychosocial behavior, the impact of chronic lactulose therapy on mental function in cirrhotics without overt encephalopathy appears to be limited.

Adult↗